Safety of COVID-19 mRNA Vaccines in Patients with Cancer Enrolled in Early-Phase Clinical Trials
Article
[키워드] adverse effect
adverse event
AEs
anticancer
approved drugs
cancer patient
Cancer patients
clinical
clinical trial
clinical trials
cohort study
Compound
compounds
COVID and cancer
COVID-19
COVID-19 vaccination
COVID-19 vaccine
COVID-19 vaccines
development
division
drug
drug combinations
early-phase clinical trials
Efficacy
Efficacy and safety
enrolled
Enrollment
European
first dose
General population
Immune checkpoint inhibitors
Immunotherapy
include
investigated
Local
Mild
moderate
MOST
mRNA
New
novel immunotherapy
Patient
Patients with cancer
phase one trial
profiles
question
receive
receiving
required
retrospective
Safe
Safety
safety profile
SARS-CoV-2
second dose
simple
solid tumors
Support
systemic AEs
targeted therapy
the patient
the vaccine
treated
Treatment
Trial
trials
Vaccine
[DOI] 10.3390/cancers13225829 PMC 바로가기 [Article Type] Article
[DOI] 10.3390/cancers13225829 PMC 바로가기 [Article Type] Article